Bo Lan
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
-
- MicroRNA in disease regulation
Papers in
- Oncology 23
- HER2/EGFR in Cancer Research 6
- Cancer survivorship and care 5
- Cancer Treatment and Pharmacology 4
- Cancer Immunotherapy and Biomarkers 3
-
- Cancer Genomics and Diagnostics 2
- Breast Cancer Treatment Studies 2
- Co-authors
- Binghe Xu (18 shared papers)Fei Ma (26 shared papers)Hongnan Mo (13 shared papers)Xuelian Chen (6 shared papers)Dawei Wu (6 shared papers)Jing Huang (4 shared papers)Dong Qu (3 shared papers)Xingyuan Wang (4 shared papers)
- Journals
- International Journal of Cancer (4 papers)The Breast (4 papers)Therapeutic Advances in Medical Oncology (3 papers)Clinical Breast Cancer (2 papers)Clinical Cancer Research (2 papers)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Bo Lan
48 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 82
- Oncology 460
- Cancer Research 114
- Pulmonary and Respiratory Medicine 194
- Applied Microbiology and Biotechnology 9
- Hepatology 30
Countries citing papers authored by Bo Lan
This map shows the geographic impact of Bo Lan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Lan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Lan more than expected).
Fields of papers citing papers by Bo Lan
This network shows the impact of papers produced by Bo Lan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Lan. The network helps show where Bo Lan may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Lan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 186 | |
| 2 | 2018 | 165 | |
| 3 | 2018 | 134 | |
| 4 | 2019 | 72 | |
| 5 | 2018 | 58 | |
| 6 | 2019 | 55 | |
| 7 | 2019 | 40 | |
| 8 | 2018 | 32 | |
| 9 | 2018 | 27 | |
| 10 | 2019 | 23 | |
| 11 | 2020 | 22 | |
| 12 | 2020 | 18 | |
| 13 | 2018 | 17 | |
| 14 | 2022 | 15 | |
| 15 | 2019 | 14 | |
| 16 | 2022 | 12 | |
| 17 | 2020 | 12 | |
| 18 | 2017 | 10 | |
| 19 | 2024 | 10 | |
| 20 | 2021 | 9 |
About Bo Lan
Bo Lan is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Epidemiology and Pharmacology, having authored 55 papers that have together received 1.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (5 papers), Cancer survivorship and care (5 papers), Cancer Treatment and Pharmacology (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Genomics and Diagnostics (2 papers), Estrogen and related hormone effects (2 papers) and Breast Cancer Treatment Studies (2 papers). The work is most often cited by research in Oncology (460 citations), Cancer Research (114 citations), Pulmonary and Respiratory Medicine (194 citations), Applied Microbiology and Biotechnology (9 citations) and Hepatology (30 citations). Bo Lan has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Binghe Xu, Fei Ma, Hongnan Mo, Xuelian Chen, Dawei Wu, Jing Huang, Dong Qu, Xingyuan Wang, Qing Yang and Shanshan Chen. Their work appears in journals such as International Journal of Cancer, The Breast, Therapeutic Advances in Medical Oncology, Clinical Breast Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.